Adjust Font Sizing:

Educational Material

Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA

Avadel Pharmaceuticals plc announced the submission of its New Drug Application to the US Food and Drug Administration (FDA) for FT218, an investigational, once-nightly formulation of sodium […]

Positive Results from IH Phase 3 Study of Xywav

Jazz Pharmaceuticals plc announced positive top-line results from their Phase 3 double-blind, multicenter, placebo-controlled, randomized withdrawal study evaluating the efficacy and safety of an investigational use of […]